Interviews

Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses a phase II study of whole brain radiotherapy with concurrent lapatinib in patients with brain metasteses from HER2-positive breast cancer.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses a phase II trial looking at ONT-380 in HER2+ breast cancer. 

Evanthia Galanis, MD, professor of oncology, Mayo Clinic, discusses how to best optimize clinical trial design in brain cancer and other cancer types.

Jennifer Woyach, MD, associate professor, Ohio State University, discusses a study combining MOR208 with Lenalidomide for the treatment of chronic lymphocytic leukemia (CLL). 

Howard Fine, MD, director, Brain Tumor Center, Weill Cornell Medicine, discusses the history of metabolic targets in brain cancer.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses studies evaluating second-line treatment options in bladder cancer.

Tim F. Greten, MD, senior investigator, Thoracic and Gastrointestinal Oncology Branch, and head, Gastrointestinal Malignancy Section, National Cancer Institute Center for Cancer Research, discusses the possibility for immunotherapy in liver cancer.

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the dilemma of managing a patient who has residual disease after receiving neoadjuvant therapy.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, discusses the current and emerging roles of PARP inhibition in ovarian cancer.

Thomas E. Witzig, MD, hematologist-oncologist, Mayo Clinic, discusses some of the issues that still need to be addressed in diffuse large B-cell lymphoma.

Deepak A. Kapoor, MD, Chairman and CEO of Integrated Medical Professionals, discusses how physicians can adapt to the new value-based payment models.

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future of thyroid cancer treatment.

Navesh K. Sharma, DO, PhD, associate professor of Radiology, Division of Radiology and Oncology, Penn State Hershey Medical Center, section chief of Radiation Oncology, Penn State Health St. Joseph Cancer Center, discusses the results of the SIRFLOX study in patients with metastatic colorectal cancer (mCRC).

David A. Reardon, MD, clinical director, center for neuro-oncology, Dana-Farber Cancer Institute, discusses the inadequacy of the current standard of care in glioblastoma (GBM).

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, speaks on distinguishing between the different subtypes of sarcomas.

Raoul Concepcion, MD, director, Comprehensive Prostate Center, discussed the best treatment option for a patient with metasatic castration-resistant prostate cancer (mCRPC) during the LUGPA Annual Meeting.

Jeffrey Schneider, MD, chief of hematology and medical oncology, Winthrop University Hospital, discusses the benefits of Myriad's myPlan in determining high-risk patients with non-small cell lung cancer (NSCLC).

Debu Tripathy, MD, chair, Breast Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the potential for immunotherapy in the treatment of HER2+ breast cancer.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses the future of biomarkers in prostate cancer.

Howard S. Hochster, MD, professor of Medical Oncology, and Yale Cancer Center Associate Director (for Clinical Sciences), discusses steps that can be taken to tackle some of the challenges that remain in the field of pancreatic cancer.

Steven Coutre, MD, professor of medicine, Stanford University School of Medicine, discusses the benefits and drawbacks of the different frontline treatment options for chronic lymphocytic leukemia (CLL).

Caroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussy in Paris, discusses overall survival (OS) results of a recent study evaluating dabrafenib and trametinib in melanoma.

Toni Choueiri, MD, discusses some of the ongoing clinical trials in metastatic renal cell carcinoma (mRCC).

Lidija Kandolf-Sekulovic, MD, PhD, associate professor of Dermatology at the Military Medical Academy in Belgrade, Serbia, discusses a recent survey that examined the lack of access to lifesaving drugs in European melanoma patients.

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses his vision for breast cancer treatment in the next 5 to 10 years.

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses how mutation status effects individualization of treatment in metastatic colorectal cancer (mCRC).

Toni Choueiri, MD, discusses the results of the ALLIANCE A031203 trial comparing cabozantinib and sunitinib in metastatic renal cell carcinoma (mRCC).

Kiran Turaga, MD, MPH, surgical oncologist, University of Chicago Cancer Center, discuses exciting advancements in the field of sarcoma.

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the future role of PD-L1 testing in lung cancer.